Intervention: Entecavir
Trial phase: Phase 2
ATC code: J05AF10
SMILES: C=C1[C@H](CO)[C@@H](O)C[C@@H]1n1cnc2c(=O)nc(N)[nH]c21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 189
Group description: Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.

Therapeutic HBV vaccine: Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.

entecavir: 0.5mg,per day,oral intake.
Eligibility criteria:
Inclusion Criteria:

Aged 18-65 years, male or female;

Conforming to diagnosis standard of chronic hepatitis B according to " 2005 Guideline for Prevention and Treatment of Hepatitis B " , (with positive HBsAg for more than 6 months), never have systemic treatment of anti-HBV viral ,and

HBV-DNA ≥ 1.72×10^4 IU/ml；
HBeAg (+), HBeAb (-)；
ALT within 2 to 10 times of ULN (upper limits of normal);
HLA-A2 positive;

Compensatory liver disease having following hematological and biochemical parameters:

WBC ≥ 3.5×10^9/L;
ANC ≥ 1.5×10^9/L;
PLT ≥ 80×10^9/L;
Hb ≥ 100g/L;
TBil ≤ 1.5 ULN;
ALB not lower than low limit of normal value;
BUN no more than high limit of normal value;
Cr ≤ 1.5 ULN high limit of normal value;
PT elongation ≤ 3 sec, APTT in normal value;
Fasting blood glucose ≤ 7.0mmol/L;
TSH in normal value;
AFP test result no more than high limit of normal value;
Take effective contraception for subject with child-bearing potential (including females and female partners of males);
Understand and sign ICF approved by EC;
Willing to comply with the study procedures and complete the study.

Exclusion Criteria:

Antibodies of HCV, HDV or HIV is positive;
ANA titer > 1:100;
Decompensated liver disease (such as gullet and pylorus varicose veins, hepatic encephalopathy);

Have the following illness or with severe disease inappropriate to participate in the study in the view of the investigator, in cardiovascular system: instable or significant cardiovascular illness such as angina pectoris, heart attack of myocardial infarction, congestive heart failure, severe hypertension, significant arrhythmia or abnormal ECG etc;

Respiratory system: bronchiectasia, bronchial asthma, chronic obstructive pulmonary disease, respiratory failure, etc;
Endocrine, metabolism diseases: diabetes mellitus, uncontrolled thyroid diseases, etc;
Others: autoimmune disorder, active tuberculosis, malignancies (e.g.: tumor), neuropathic, metal, acute or chronic pancreatitis illness history, etc.
Have used anti-HBV drug ( Interferon, Lamivudine, Adefovir Dipivoxil, Entecavir and Telbivudine ) and immunomodulator ( Thymic peptide, etc ) to the administration of study medication;
Have allergic diathesis or have suspected allergy to εPA-44;
Female in pregnancy, lactation or those who plan to pregnancy during the course of the study;
Have history of alcohol abuse (Alcohol consumption for more than 5 years, with daily consumption over 40g for males and over 20g for females) and known drug dependence;
Have history of organ transplantation (except corneal transplantation and hair transplantation);
Have participated in any other drug clinical investigations within 3 months;
Any other factors inappropriate for enroll in the study or study completion in the view of the investigator.